6.66 +0.25 (3.98%)
Pre-Market: 8:50AM EDT
|Bid||6.70 x 1100|
|Ask||6.70 x 1000|
|Day's Range||6.38 - 6.68|
|52 Week Range||3.75 - 16.86|
|Beta (3Y Monthly)||3.81|
|PE Ratio (TTM)||21.44|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CALGARY , May 24, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that it has closed the acquisition of Dreamweavers Cannabis Products Inc. ("Dreamweavers"), a retail cannabis store and e-commerce business currently operating in Swift Current, Saskatchewan as licensed by the Saskatchewan Liquor and Gaming Authority. The consideration paid to close the acquisition of Dreamweavers was $1,550,000 in cash and 3,100,000 of the special warrants previously authorized for issuance on December 14, 2018 , consisting in aggregate of 3,100,000 common shares of High Tide and 1,550,000 purchase warrants exercisable at $0.75 per common share of High Tide.
Since February, cannabis maker Cronos Group (NASDAQ:CRON) has been on a downward slide. Note that CRON stock has gone from $22 to $15.30.Yet keep in mind that the poor performance of Cronos Group stock has not been an outlier. General bearishness towards marijuana stocks has become prevalent. Just look at companies like Tilray (NASDAQ:TLRY) and Aphria (NYSE:APHA). Among the reasons for the slide are that the sector has already had a big run-up, there are concerns about marijuana supply, and pricing has been showing some weakness.The weakness of CRON stock may be an opportunity, even though the valuation of Cronos Group stock is still not attractive. Even following the decline, CRON stock is still trading at nose-bleed levels. Consider that the market cap of CRON stock is at $5.2 billion, while its first-quarter sales came in at a mere CA$6.5 million. That kind of valuation is reminiscent of the wild dot-com boom of the 1990s.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 6 Stocks to Buy for This Decade's Massive Megatrend There are also some nagging issues with the fundamentals of CRON stock. Perhaps the most important problem is its production or lack thereof. In Q1, its production soared 122% year-over-year, but it still only made 1,111 kilos. That is relatively low, compared to other major cannabis players like Canopy Growth (NYSE:CGC).While this is worrisome, there are still notable bullish factors. In fact, in terms of production, CRON has been investing heavily in expanding its capacity. To this end, the company's Building 4 facility -- which is 286,000 square feet -- will soon come online.Next, another big advantages for CRON stock is its balance sheet. Tobacco powerhouse Altria (NYSE:MO) invested a hefty CA$2.4 billion in Cronos Group stock for a 45% stake in Cronos. In other words, CRON will have more than sufficient resources to bolster its production.But the MO deal will be more than just about capital. There will also be major synergies that should help to accelerate the growth of CRON and boost Cronos stock. Examples include: * MO brings deep capabilities of design, manufacturing, marketing, distribution and commercialization. * The company has expertise that can help with cannabis vape products. * It has a strong background in dealing with complex regulatory issues, including taxes, product registration, shipping, licensing and government affairs. The Bottom Line on CRON StockEven with the volatility of CRON stock, it's important to keep in mind that the growth prospects of the cannabis industry still look very promising. Based on research from the United Nations, about $150 billion is spent on cannabis across the globe, and there are roughly 180 million people who consume cannabis.There is also the quickly emerging category of cannabidiol (CBD) -- a compound found in the sativa plant that does not produce a high - which has shown medical efficacy. Congress' legalization of CBD is expected to turn it into a big market in the U.S. Brightfield Group forecasts that the market will be worth $22 billion by 2022.CRON stock is positioned nicely to benefit from these trends. But more importantly, the company has the scale, infrastructure, brands and resources to be a long-term winner.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.Compare Brokers The post Can Cronos Stock Be a Long-Term Winner? appeared first on InvestorPlace.
Canopy Growth: Analysts' Views in May(Continued from Prior Part)Canopy Growth’s valuationCanopy Growth (WEED) (CGC) is one of the few stocks that has traded at premium valuation multiples compared to its peers like Aurora Cannabis (ACB), Aphria
Cronos Group (NASDAQ:CRON) has established its own trend. Thanks to the $1.8 billion investment that CRON received from Altria (NYSE:MO) in December, Cronos is one of the few pot stocks whose 52-week high didn't come right before marijuana became legal in Canada in October.After that announcement, CRON stock began a bull move that peaked in March. Unfortunately, CRON stock has fallen since that time. Since there's no apparent upcoming catalyst that can break that downtrend, traders don't have an incentive to take a chance on Cronos Group stock. CRON Stock Can't Become a Market LeaderSince reaching a near-term peak of $24.37 per share on Mar. 6, CRON stock has steadily slid. Now many wonder when the decline will end.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy for Over 20% Upside Potential Many people were bullish on CRON stock after U.S. tobacco giant Altria acquired a stake in the company. Because the cannabis and marijuana industries have certain similarities. I think this alliance will give Cronos some added expertise in the areas of production, distribution, and marketing. It also reminded many of Constellation Brands' (NYSE:STZ) investment in Canopy Growth (NYSE:CGC) that made CGC a market leader.However, for all of the talk about CRON stock, analysts only expect CRON to produce about 130,000 kg of pot this year. That trails smaller firms such as Aphria (NYSE:APHA) and The Green Organic Dutchman (OTCMKTS:TGODF). Valuation, Charts Show Little Reason to Buy Cronos StockMarijuana stocks remain highly speculative. For traders to take a chance on a marijuana stock, they need some reason to believe that they can sell it at a higher price later. Because CRON lags some smaller firms in production, it has little chance of leading the industry. Today Aurora Cannabis (NYSE:ACB) and Canopy Growth have emerged as industry leaders.The multiple of CRON stock also doesn't give investors a reason to buy the shares. Cronos stock currently trades at around 355 times CRON's sales. While that might appear elevated, it compares well to other cannabis equities in today's market.CRON does deserve credit for earning a profit. Cronos Group reported a first-quarter GAAP profit of 48 Canadian cents (36 cents) per share. CRON predicts that its 2019 EPS will come in at 52 Canadian cents (39 cents). That would gives CRON a price-earnings ratio of about 35.6. However, due to an expected decline in CRON's EPS to 7 Canadian cents (5.2 cents) in 2020, its forward PE comes in at 290.That valuation leaves investors with little incentive to buy Cronos stock. I have made successful short-term trades in the past in both Aphria and CannTrust Holdings (NYSE:CTST), due to their relatively low multiples. It is possible to find stocks with attractive valuations in the cannabis space. Unfortunately, that does not apply to CRON stock at this time.Finally, the recent price movements of Cronos Group stock also won't help traders much. From a technical perspective, InvestorPlace columnist Bret Kenwell thinks that Cronos stock has support in the $13-$14 per share range. However, if CRON falls below that level, it could return to the single digits. Over the last year, it has appeared to build a floor in the $6 per share range. Cronos stock would be attractive at that level. Still, it will probably not reach that price anytime soon. Final Thoughts on CRONThere's nothing attractive about Cronos Group stock for investors or speculators. I can see a lot to like about Cronos Group's business. Its alliance with Altria should help it with production, distribution, and marketing. Also, the fact that it earns a GAAP profit will place CRON in a strong position compared to many of its peers.Unfortunately, none of those advantages make Cronos Group stock attractive. Cronos' production levels lag those of market leaders such as Aurora and Canopy. The valuations of those names are also more favorable than that of CRON stock, closing off any chance that CRON could be seen as a relative bargain. Moreover, while Cronos stock could bounce off of key resistance points, the stock's floor is well below its current levels.I have stated on many occasions that marijuana equities like CRON stock will eventually become low-multiple, dividend-paying equities like the Altria of today. Until CRON develops those characteristics, or at least finds a more solid floor, I would look to own other equities in the cannabis space.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for Over 20% Upside Potential * 5 Large-Cap Stocks Holding Steady Amid Trade War Concerns * 7 ETFs for Healthy Healthcare REITs Compare Brokers The post Cronos Stock Is Less Attractive Than Many Other Marijuana Names appeared first on InvestorPlace.
Aphria Stock Rises on Cultivation License in GermanyAphria receives a licenseToday, Aphria (APHA) announced that it received its fifth license to cultivate cannabis in Germany. The company stated that, with the approval of this fifth license, it
CALGARY , May 21, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that Canna Cabana was selected by random algorithmic draw as the Successful Retailer for the community of Niverville during Manitoba's Cannabis Retail Opportunities Draw (the "Draw") held on May 15 , 2019. The opportunity will permit Canna Cabana to be licensed by the Liquor, Gaming and Cannabis Authority of Manitoba to operate a bricks-and-mortar retail store in Niverville as well as e-commerce sales serving the entire province. As the parent company of Canna Cabana, High Tide has confirmed its interest in the Niverville license.
LEAMINGTON, ON , May 21, 2019 /CNW/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today announced that its German subsidiary Aphria Deutschland GmbH ("Aphria Germany") had been awarded a fifth lot for the cultivation of medical cannabis in Germany as part of the Company's previously awarded license from the German Federal Institute for Drugs and Medical Devices ("BfArM"). The additional lot was provisionally awarded to Aphria Germany in April and was secured following a review by a German court, which affirmed the original decision by the BfArM.
Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.
CALGARY , May 17, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that Canna Cabana has been granted membership into the Canadian Franchise Association ("CFA"). High Tide is now in possession of a Certificate of Membership for both the Smoker's Corner retail smoking accessories business and the Canna Cabana retail cannabis business, which is unique in Canada .
Markets Rebound but Cannabis Stock Performance Is Mixed(Continued from Prior Part)Sector mixedThe cannabis sector is largely mixed today. Whereas Canopy Growth (WEED), CannTrust, Aphria, and a few others have fallen, some stocks have risen.Sign
Canopy Growth (NYSE:CGC) just isn't getting as high as it used to. But CGC stock isn't alone. The marijuana stocks have lost a lot of their buzz lately. The sector fund, the Alternative Harvest ETF (NYSEARCA:MJ) has dropped roughly 15% from its recent highs in March. On top of that, its current $33 share price is well off the $45 level where marijuana stocks peaked just before Canada's legalization went into effect last fall.Source: Shutterstock CGC stock has fared better than many of its rivals. But its stock hasn't been able to hit new highs in awhile either, as the $50 price level has been key resistance. With the company making major acquisitions ahead of earnings and short sellers betting the farm against the stock, expect CGC stock to make big moves in coming weeks. CGC Stock ConsAcreage Deal Isn't A Standard Acquisition: Canopy Growth recently announced a deal to purchase Acreage Holdings (OTCMKTS:ACRGF). This deal is a rather odd one for a number of reasons.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy that Lost 10% Last Week To start with, the deal is contingent on the U.S. legalizing marijuana federally. The deal is structured with a 90 month (7 and a half years) time limit. It will be terminated if federal legalization doesn't occur within that time frame. As it is, Canopy is taking some risk. That is because it is paying a not insubstantial $300 million upfront for the deal, along with far more than that in CGC stock once the deal closes.Given that the deal could take ages to close, Canopy could be giving up a lot of value with its shares. That will depend on where the share price is in coming years. Additionally, there's a risk that Acreage shareholders will oppose the deal, as Canopy is offering a rather modest premium for the acquisition.CGC Stock Hitting Major Resistance: From a technical analysis standpoint, Canopy Growth stock is starting to get itself into trouble. For the better part of a year now, CGC stock has stopped dead in its tracks every time it reaches near the $50 mark.Canopy Growth stock first hit the $50 level last fall. It spent the better part of September trading around that figure. Shares subsequently dumped all the way to $25. But CGC stock bounced back, hitting $50 again in January. That rally petered out, and shares declined 20%. In April, CGC stock again briefly reclaimed the $50 level but has already dropped back almost 15% since that point. $50 is turning into a major resistance point for Canopy stock. Going forward, bulls need to get the stock to close above $50 before serious trading momentum can get going again.Valuation Is Still Strained: Canopy Growth -- and most of its publicly traded rivals that focus on recreational marijuana -- have yet to deliver compelling earnings. In fact, for many firms, free cash burn has actually gotten worse. Companies keep ramping up their growth expenses without enough revenues to offset those costs just yet.Already, we're starting to see issues on the revenue side. The price of recreational marijuana keeps dropping, sales volumes are flattening out, and producers seemingly have a huge oversupply of marijuana on hand. Canopy still has time to find its way to profitability thanks to the Constellation (NYSE:STZ) cash infusion. But it's burning through that money awfully quickly.Not only are the operations losing money, but it keeps making big purchases like Acreage and the German deal announced earlier this month for close to another $250 million. CGC Stock ProsDeals Could Pay Off Big: While these latest deals certainly come with risk, they could pay off for Canopy. The German deal, acquiring the C3 Cannabinoid Compound Company looks interesting in particular. C3 has developed various products to treat pain in cancer patients, among other uses.C3 already has a healthy $30 million or so in annual revenues. This suggests that Canopy only paid about 8x annual sales for the deal. Compared to many of the deals going off in the hyped-up marijuana space, that's a defensible valuation. $30 million in (presumably fast-growing) annual revenues will be enough to move the needle for Canopy Growth more generally as well.CGC Stock Holding Up Better: Canopy Growth stock is having a mighty difficult time trying to break out above the $50/share level. But at least it is still somewhere near its recent trading highs.Other pot stocks have gotten crushed lately. Cronos (NASDAQ:CRON), Aurora (NYSE:ACB) and Aphria (NASDAQ:APHA) have all fared worse than Canopy. There's a lot of value in being the strongest performing major stock within the industry. When marijuana stocks rally as a group, it may be enough to power CGC stock past that $50 barrier and onward to new all-time highs.Short Squeeze Potential: As I sometimes warn, you generally shouldn't base a whole investment thesis on the potential for a short squeeze. That said, if you are already considering taking a long position, high short interest could be the thing that causes the stock to run in the short term.Canopy Growth's stock has an incredible 75 million shares shorted (on its U.S. listing). That makes up 35% of the float. This is among the highest short ratios you'll find out there for a large widely-traded stock today. Clearly short sellers are betting on Canopy's next earnings report being a dud. That would be in line with what other pot players have produced recently. But if they're wrong, the stock could make a violent move higher. CGC Stock VerdictI don't see this as a great time to get into CGC stock. The firm has outperformed its other marijuana peers recently. But a poor earnings report could drive CGC stock right back down with the rest of the pack. Given how strong the $50 resistance level has been, bears are logically pressing their bets here. * 3 Reasons Not to Sell Canopy Growth Stock If Canopy Growth can deliver a strong earnings report, that would change everything. But until investors see a clearer path to profits and a more stable business trajectory, odds will continue to favor the bears. I'd stick to the sidelines in Canopy stock for the time being.At the time of this writing, Ian Bezek held no positions in any of the aformentioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post Should You Buy Canopy Growth Stock? 3 Pros, 3 Cons appeared first on InvestorPlace.
No one who follows Aphria (NYSE:APHA stock should have been surprised that the company's president, Jakob Ripshtein, resigned on May 14. Ever since interim CEO Irwin Simon was appointed Independent Chair of Aphria's board in December, it was only a matter of time before Simon, the entrepreneurial founder and former CEO of Hain Celestial (NASDAQ:HAIN), would play a more prominent role at the Canadian cannabis company. Out With the OldSimon stepped down in June 2018 from his role as CEO of Hain after years of sub-standard shareholder returns and a hard-court press from activist investor Engaged Capital.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy that Lost 10% Last Week Simon owned 1.7% of Hain's stock, but Engaged has an 11.3% stake, so Engaged's founder, Glenn Welling, was appointed to Hain's board in September 2017. Simon remained the chairman of Hain, the same role he now holds at Aphria. At 60 and in reasonably good health, Simon probably isn't ready to devote his life to the golf course and retirement. The resignation of Ripshtein, after Vic Neufeld stepped down as APHA's CEO in January, is another part of the changing of the guard at Aphria. I expect the board to soon remove the interim tag from Simon's current title. The Irwin Simon era at APHA has begun. The New COORipshtein joined Aphria in May 2018 as its chief commercial officer and was promoted to president six months later, before Simon arrived on the scene. While Simon's words of thank to Ripshteins in the company's press release were complimentary, it's clear by Aphria's choice for COO that Simon wasn't comfortable working with Ripshtein, a former CFO of Diageo's (NYSE:DEO) North American operations and former president of the liquor company's Canadian operations. "On behalf of the Board of Directors and Aphria team, we thank Jakob for his contributions to the Company over the past year and wish him well in his future endeavors. He has been instrumental in assembling the incredible team we are fortunate to have today that will carry his responsibilities forward," Irwin stated in Aphria's May 14 press release.The new COO is Jim Meiers, who happens to have come to Aphria after 14 years at Hain Celestial, where he worked alongside Simon. At Hain, Meiers hed several senior executive positions, including president of Celestial Seasonings. Before Hain, he worked at both H.J. Heinz and Kraft Foods. Meiers' hiring suggests two things.First, it's likely Simon wanted someone he could trust to execute Aphria's game plan and someone who's familiar with his style of management. Every change at the top involves a little turnover. I'm sure it wasn't personal. Secondly, Meiers' background suggests that Simon is looking to implement a supply chain which is more appropriate for a food company rather than a medical company. Both, however, require significant oversight, making the appointment a sensible one and positive for Aphria stock. The Bottom Line on Aphria StockThe moves announced May 14 are simply part of the ongoing transformation of Aphria from Vic Neufeld's baby to Irwin Simon's. One of two things is going to happen in the coming months. Either Simon will be appointed the permanent CEO (likely) or Meiers will become the chief executive (less likely but still possible). Given the spotty performance of Hain stock over the past 15 years, I don't know if Simon's rise to power at APHA is, overall, a good thing or a bad thing for the owners of Aphria stock. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post New Regime Will Impact Aphria Stock appeared first on InvestorPlace.
GrowGeneration (OTCQX: GRWG) has purchased the assets of GreenLife Garden Supply, including two locations in Maine and one in New Hampshire. The acquisition brings the company's total retail and warehouse locations to five that services the growing number of commercial cultivators in the New England market. Target Group (OTCQB: CBDY) subsidiary Canary Rx has submitted a site […]The post Cannabis Stock News Daily Roundup May 15 appeared first on Market Exclusive.
CALGARY , May 15, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that it has received approval from The Depository Trust Company ("DTC") to make the Company's common shares eligible to be electronically cleared and settled through DTC ("DTC Eligibility"). DTC Eligibility makes High Tide's common shares more accessible to investors in the United States , which is expected to result in higher volumes given the additional availability of shares for trading.
Aphria Inc (NYSE: APHA ) on Tuesday announced some management changes. What Happened Aphria announced its President Jakob Ripshtein will resign from the company June 7. Ripshtein was promoted to the role ...
Amid a disappointing earnings report, Aphria (NYSE:APHA) continues on the path to recovery. Allegations regarding an asset purchase and conflicts of interest in the C suite sent Aphria stock from over $16 per share to under $4 per share for a brief time.Source: Shutterstock However, a new CEO has restored some confidence in the company. The most recent earnings numbers stopped the upward move in APHA for now.Still, with a compelling valuation and a well-regarded consumer industry executive leading the company, APHA could find itself on the way to recovery.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor the sake of full disclosure, I bought Aphria stock when it still traded on the pink sheets. However, I got out soon after it moved to the New York Stock Exchange. I made this decision when questions about conflicts of interest within the C suite and the legitimacy of its Latin American assets came to light. * 7 Dividend Stocks to Buy as the Trade War Reignites A Closer Look at AphriaFast forward to today, and both CEO Vic Neufeld and co-founder and Cole Cacciavillani have left the company. Further, a review of the purchase determined that Aphria paid a high but acceptable price for legitimate assets in Latin America.Aphria has now appointed Irwin Simon as its interim CEO. Simon founded Hain Celestial (NASDAQ:HAIN) in 1993. Over 25 years, he made it one of the leading natural and organic food companies in the U.S. This has helped restore some confidence in APHA. It also mirrors the situation at GE (NYSE:GE) who has also hired a CEO from the outside with a reputation for success.The existence of recent reputational issues tends to breed mistrust. However, it also leaves more risk-tolerant traders with reasons to buy. Aphria stock trades at a forward price-to-earnings (PE) ratio of 22.9.This comes in well below average multiples in the cannabis industry. Today, marijuana stocks often support price-to-sales (PS) ratios in the triple digits. That also appears cheap when considering predicted earnings increases. Wall Street expects profit growth of 140% this year and 75% in fiscal 2020.I think these factors take Aphria back to where it was before the controversies took place. APHA may never catch up to the likes of Canopy Growth (NYSE:CGC) or Aurora Cannabis (NYSE:ACB) in terms of valuation. Still, CGC supports a PS ratio of just over 140. That same multiple stands at around 20 for APHA stock. This leaves APHA will potential to expand that multiple. APHA Is a Buyout CandidateAnother possibility lies in a buyout. his does not mean the hostile bid like the one recently attempted by Green Growth Brands (OTCMKTS:GGBXF), but one from a larger player.I usually avoid recommending stocks for this reason (buyouts can come at any price level). However, given Aphria's low multiple, buyers will likely look to APHA rather than other cannabis firms.Moreover, it has established a presence in key markets offshore. Yes, it recently divested its U.S. assets. However, it holds the holdings in Latin America which caused issues for the company last year. This includes cultivation acreage in Colombia and Jamaica as well as research-related assets in Argentina.Also, its purchase of Nuuvera brings Aphria into Europe, the Middle East, and Africa. Further, it has recently become one of the few firms to acquire five licenses (the legal maximum) to cultivate weed in Germany. This should bring significant growth for APHA even if they never enter the U.S. Bottom Line on Aphria StockNow that the company has put conflicts of interests behind it, a speculative case for Aphria has emerged. Thanks in part to the lower stock price, the company finds itself in a position where it earns an annual profit and trades well below most of its peers in the cannabis industry.Moreover, a CEO with a track record of success runs the company. Also, though it no longer holds U.S. assets, holdings in other parts of the world should lead Aphria to further growth. Regardless of whether owners of APHA benefit from profit growth or a buyout, the future again appears bright for Aphria stock.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks to Buy as the Trade War Reignites * 10 Stocks That Could Squeeze Short Sellers, Including CGC * 5 Tech Stocks Getting Crushed Compare Brokers The post There's a Pretty Strong Speculative Case for Buying Aphria Stock appeared first on InvestorPlace.
LEADING CONSUMER PACKAGED GOODS EXECUTIVE TO LEAD APHRIA AS CHIEF OPERATING OFFICER ELEVATES TENURED INFORMATION AND SECURITY LEADER ADDS HUMAN RESOURCES VETERAN LEAMINGTON, ON , May 14, 2019 /PRNewswire/ ...